Aeglea BioTherapeutics, Inc. announced that effective May 16, 2023, the employment Of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of the company was terminated.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.97 USD | +2.62% | +10.98% | +76.58% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.58% | 1.49B | |
+4.60% | 111B | |
+10.71% | 105B | |
-12.22% | 22.34B | |
-3.46% | 21.93B | |
-5.85% | 18.59B | |
-36.52% | 18.12B | |
-9.80% | 16.96B | |
+3.24% | 13.7B | |
+37.03% | 12.45B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer